<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220971</url>
  </required_header>
  <id_info>
    <org_study_id>1060603</org_study_id>
    <nct_id>NCT03220971</nct_id>
  </id_info>
  <brief_title>Lipoprotein and Apolipoproteins With Metabolic Liver Diseases</brief_title>
  <official_title>Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chun-Hsiang Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tainan Municipal Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Theranostic translation applications against viral, metabolic liver diseases and hepatic
      oncogenesis: lipoprotein and apolipoproteins at a crossroad
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An intimate link between microbial infections, metabolic changes and oncogenesis has been
      drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease
      progression. Globally the burden of hepatitis B and C virus infections is 450 and 185
      millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis,
      hepatocellular carcinoma and metabolic disorders
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad</measure>
    <time_frame>2years</time_frame>
    <description>Study the interplay between hepatitis C virus (HCV) and lipid metabolism(the HCV infection affects host lipid homeostasis, regarding transportation, synthesis, and catabolism.)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Disorders of Lipoprotein Metabolism and Other Lipidaemias</condition>
  <arm_group>
    <arm_group_label>proposed cross-section study</arm_group_label>
    <description>100 subjects with NAFLD/NASH and negative anti-HCV Ab
50 subjects with HCC and negative anti-HCV Ab
50 subjects with HCC and positive for genotype-1 HCV
50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV
50 controls with all negative for NAFL, NASH and HCV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>proposed longitudinal study</arm_group_label>
    <description>50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR
10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR
10 HCC patients and positive for genotype-1 HCV with SVR
10 HCC patients and positive for genotype-1 HCV without SVR
50 chronic hepatitis C but not NAFLD patients with SVR
10 chronic hepatitis C but not NAFLD patients without SVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lipoprotein and apolipoproteins</intervention_name>
    <description>To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases</description>
    <arm_group_label>proposed cross-section study</arm_group_label>
    <arm_group_label>proposed longitudinal study</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biochemical blood: GOT, GPT, HDL, LDL, TG, insulin, AC sugar
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        An intimate link between microbial infections, metabolic changes and oncogenesis has been
        drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease
        progression. Globally the burden of hepatitis B and C virus infections is 450 and 185
        millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis,
        hepatocellular carcinoma and metabolic disorders
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. above 20 years

          2. nonalcoholic fatty liver disease

          3. Non-Alcoholic Steatohepatitis

        Exclusion Criteria:

        1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chun-Hsiang Wang</name>
      <address>
        <city>Tainan</city>
        <zip>701</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tainan Municipal Hospital</investigator_affiliation>
    <investigator_full_name>Chun-Hsiang Wang</investigator_full_name>
    <investigator_title>Tainan Municipal Hospital</investigator_title>
  </responsible_party>
  <keyword>Lipoprotein and Apolipoproteins metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

